Sentences with phrase «months ending march»

For the 12 months ending March 2013 the median international home price was $ 275,862.

Microsoft sold 1.2 million Xbox One consoles during the three months ending March 31st.

Microsoft's devices and consumer hardware division, which houses Xbox, generated nearly $ 2 billion for the three months ending March 31st, up almost $ 600m from the same period last year.

Microsoft's Devices and Consumer Hardware Division, home to its Xbox operations, reported revenues of $ 1.97 bn for the quarter and $ 8.19 bn for the nine months ending March — both up from $ 1.4 bn and $ 5.29 bn respectively.

Perhaps the most frightening announcement, though is this: Assassin's Creed III will be released sometime within «the 12 months ending March 2011.»

LATAM Airlines Group has announced total operating revenues increased by 6.4 per cent to $ 2,477 million for the three months ending March 31st.

So your worst - case 1 - year return will be 1.53 %; this assumes 0 % inflation for the six months ending March 31, 2012.

For example, over the 12 months ending March 31 the iShares S&P / TSX Capped Composite (XIC) lagged its index by 29 basis points:

Nomura Securities estimates that electricity supply could fall about 5 % to 10 % short of demand because of power outages in the tsunami - affected areas during the 12 months ending March 31, 2012.

For the three months ending March 31, Egencia's revenue rose 23 percent year over year to $ 151 million, while adjusted earnings before interest, taxes, depreciation and amortization fell 2 percent to $ 27 million.

Within the $ 520 billion RBC Investor & Treasury Services All Plan universe — the industry's most comprehensive universe of Canadian pension plans — defined benefit (DB) pension assets returned 4.8 per cent during the three months ending March 31, 2014, bringing 12 month totals to 14.8 per cent.

Net profit for the three months ending March 31 came to 177 billion won (US$ 164.7 million), compared with a net profit of 341.8 billion won a year earlier, the company said in a statement.

The net cash outflow in the 12 months ending March 30, 2003, amounted to 3.6 percent of the sector's assets.

Data for 3 months ending March 2017.

Profit attributable to common stock rose to $ 692 million, or 47 cents per share, in the three months ended March 31, from $ 228 million, or 16 cents a share, a year earlier.

It said production in the three months ended March 31 fell by about 10 per cent to 300,400 boe / d compared to the first quarter of 2017.

Net income attributable to shareholders tripled to $ 151 million, or 60 cents per share, in the three months ended March 31.

Yum shares fell 5 percent in premarket trading on Wednesday after results showed sales at restaurants open at least a year rose 1 percent in the three months ended March 31, compared with the 2 percent expected by analysts, according to Thomson Reuters I / B / E / S.

TORONTO, May 03, 2018 (GLOBE NEWSWIRE)-- Dalradian Resources Inc. (TSX: DNA)(AIM: DALR)(«Dalradian» or the «Company») announces results for the three months ended March 31, 2018, including closing cash and cash equivalents of $ 126.9 million1.

Sales at Yum restaurants open at least a year rose 1 percent in the three months ended March 31, compared with the 2 percent expected by analysts, according to Thomson Reuters I / B / E / S.

Expenditures on mineral property under development for the three months ended March 31, 2018 were $ 6.1 million compared with $ 2.5 million, net of expected receipt from processing of mineralized material, during the comparable period in 2017.

Square acknowledged that it had taken a small hit on Bitcoin, though not enough to merit recording an impairment charge: «Losses on Bitcoin for the three months ended March 31, 2018 were insignificant,» the company wrote in the report.

This selected financial information should be read in conjunction with the consolidated financial statements and notes thereto included in Alkermes plc's Annual Report on Form 10 - Q for the three months ended March 31, 2018, which the company intends to file in April 2018.

Adjustments to operating income for the three months ended March 31, 2017 consist of $ 1.9 million of restructuring charges and merger and acquisition expenses.

Adjustments to the provision for income taxes for the three months ended March 31, 2018 and March 31, 2017 consist of $ 1.1 million and $ 0.6 million, respectively, of tax expense related to the excluded items discussed above.

Adjustments to earnings before income taxes for the three months ended March 31, 2018 and March 31, 2017 consist of the adjustments to operating income discussed above.

Results for the three months ended March 31 were as follows:

The following table provides the components of production costs for the three months ended March 31, 2018 and 2017:

See the attached schedules for supplemental financial data and corresponding reconciliations of the non-GAAP financial measures referred to above to the most comparable GAAP financial measures for the three months ended March 31, 2018.

See the attached Supplemental Financial Information for a reconciliation of net loss, a GAAP measure, to adjusted EBITDA, a non-GAAP measure, for the three months ended March 31, 2018 and 2017.

The following table provides production and weighted - average sales price, by area, for the three months ended March 31, 2018 and 2017, excluding net settlements on derivatives and TGP:

Gain related to interest rate swaps The company recognized a pre-tax gain of $ 14 million in the three months ended March 31, 2018, within interest and other expense, net related to certain forward - starting interest rate swaps for which the planned timing of the related forecasted debt was changed.

During the three months ended March 31, 2018, the company reversed $ 3 million of accrued expenses no longer required.

Acquisition integration costs Within the company's AMEA segment, in connection with the acquisition of a biscuit operation in Vietnam in 2015, the company recorded integration costs of $ 1 million in the three months ended March 31, 2018 and $ 1 million in the three months ended March 31, 2017.

Adjusted for distributions on convertible units of $ 244 for the three months ended March 31, 2018.

(2) Adjusted for earnings attributable from participating securities of ($ 599) and ($ 531) for the three months ended March 31, 2018 and 2017, respectively.

Funds from operations would be increased by $ 264 and $ 229 for the three months ended March 31, 2018 and 2017, respectively.

Net profit for the 12 months ended March 31 totaled 109.6 million pounds ($ 217.3 million), up from 70.7 million pounds the previous year.

These costs were not allocated to the reportable segments» gross profit for the three months ended March 26, 2017 because they represent an adjustment which does not provide comparability to the corresponding prior period and therefore were not reviewed by the CODM when evaluating segment performance and allocating resources.

For the three months ended March 31, 2017, the adjustment related primarily to severance expenses associated with our restructuring initiative.

The technology and business consulting firm says the profit amounted to 94 cents per diluted share for the three months ended March 31.

Excluding non-cash stock - based compensation, selling, general and administrative expenses were $ 40,205 and $ 31,343 for the three months ended March 31, 2018 and 2017, respectively, and research and development expenses were $ 11,202 and $ 10,300, respectively, for the same periods.

The company recognized licensing revenue of $ 0.1 million and $ 0.3 million in the three months ended March 31, 2018 and 2017, respectively, related to agreements for the commercialization of Vascepa outside the United States.

Selling, general and administrative expenses in the three months ended March 31, 2018 and 2017 were $ 43.4 million and $ 34.2 million, respectively.

BEDMINSTER, N.J. and DUBLIN, Ireland, May 02, 2018 (GLOBE NEWSWIRE)-- Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced financial results for the three months ended March 31, 2018, and provided an update on company operations.

These sources reported estimated normalized total Vascepa prescriptions of approximately 381,000 and 392,000, respectively, for the three months ended March 31, 2018, representing growth of approximately 25 % and 27 %, respectively, over levels reported for the first three months of the prior year.

BK Adjusted EBITDA includes $ 1.2 million of cash distributions received from equity method investments for the three months ended March 31, 2018.

Research and development expenses in the three months ended March 31, 2018 and 2017 were $ 11.8 million and $ 10.8 million, respectively.

AND SUBSIDIARIES Non-GAAP Financial Measures Organic Growth in Revenue and Adjusted EBITDA Three Months Ended March 31, 2018 (Unaudited)

Cost of goods sold for the three months ended March 31, 2018 and 2017 was $ 10.6 million and $ 8.2 million, respectively.